Treatment: Non-Small Cell Lung Cancer in China - New Market Research Report
The treatment of non-small cell lung cancer (NSCLC) in China provides a great commercial opportunity for pharmaceutical companies. Datamonitor surveyed 60 pulmonary oncologists treating NSCLC in mainland China (excluding Hong Kong and Macau) to gain insight into NSCLC diagnosis, patient segmentation, treatment patterns, and prescribing influences.
View full press release